Journal of Cosmetic Dermatology最新文献

Background: Exosomes derived from human cells have emerged as promising biological agents for enhancing skin quality through stimulation of collagen remodeling and angiogenesis. While their role in wound healing is well established, their effects on intact, non-injured skin remain insufficiently investigated. Their biological activity depends on their molecular cargo, including growth factors, extracellular matrix-modulating proteins, and angiogenic microRNAs.

Objective: To evaluate the impact of intradermal injection of two human-derived exosome formulations on dermal architecture and vascular density in intact skin.

Methods: A total of 96 adult male Syrian golden hamsters were randomly assigned to four equal groups: untreated control, saline injection, Cell Exosome (0.1 mL), or ASCE+ Exosome (0.1 mL). Skin biopsies were collected at baseline, day 3, day 7, and day 14 post injection, with equal numbers of animals sacrificed per group and time point. Histological analyses (Hematoxylin & Eosin, Masson's Trichrome, Van Gieson) assessed dermal architecture and collagen organization, while CD34 immunohistochemistry quantified microvascular density. Quantitative image analysis was performed using ImageJ, with five high power fields evaluated per specimen. All assessments were performed in a blinded manner.

Results: Untreated control and saline groups showed no significant histological or immunohistochemical changes across all time points, consistent with normal tissue architecture. Cell Exosome treatment produced moderate increases in collagen deposition and CD34 positive vessels. Quantitatively, ASCE+ increased collagen density and microvascular counts compared with Cell Exosome (p < 0.05), whereas control and saline groups showed no measurable changes.

Conclusions: Human derived exosomes promote collagen remodeling and angiogenesis in intact skin, with ASCE+ Exosome exhibiting superior efficacy over Cell Exosome. These findings highlight the potential of exosome-based therapies as minimally invasive strategies for skin rejuvenation.

Introduction: Chemotherapy-induced alopecia (CIA) is known to have a significant psychological and quality of life impact. Although cold caps have been shown to prevent CIA, expense and extension of treatment durations are barriers for routine clinical use. Keratinocyte growth factor (KGF) has been shown to have cytoprotective effects on human hair follicles and reduce alopecia in preclinical models. We hypothesized that KGF-hair serum (KGF-HS) will prevent CIA.

Methods: We conducted a Simon two-stage, single-arm clinical study in women with early-stage breast cancer (ESBC) scheduled to receive at least four cycles of chemotherapy. The primary outcome was preservation of hair after chemotherapy, whereas secondary measures included patient-reported wig use, comfort, and validated quality-of-life instruments (EORTC QLQ-C30, HADS, and BIS).

Results: Twenty patients were evaluable for the primary end point. None achieved meaningful hair preservation. The average duration of treatment of KGF-HS application was 4.6 weeks.

Conclusion: In this study of women with ESBC receiving chemotherapy, using the KGF-HS did not prevent CIA. There was no statistical difference pre- and post-study BIS, HADS, and EORTC-30 scores. Application of the KGF-HS was reported to be easy, with minimal discomfort, and a non-oily appearance. Patients' ease of use and acceptability of a topical agent for CIA further supports the development of new agents for a more practical and affordable alternative to scalp cooling.

Trial registration: clinicaltrials.gov: NCT04554732.

Background: Keloids are benign fibroproliferative tumors that often recur after surgical excision. Combining surgery with postoperative radiotherapy has emerged as a potential treatment strategy, though optimal radiotherapy protocols remain debated.

Objective: This study aims to preliminarily evaluate the efficacy and safety of a single high-dose brachytherapy session administered within 8 h after surgical excision in keloid-prone patients in a retrospective setting.

Methods: A retrospective case series analysis was conducted on 32 patients who underwent surgical excision of keloids followed by a single 8 Gy Ir-192 brachytherapy session within 8 h postoperatively. Treatment outcomes and adverse reactions were assessed over a 1-year follow-up period.

Results: Among the 32 patients, 25 were cured, 5 showed significant improvement, and 2 were ineffective, yielding a total effective rate of 93.75%. No severe radiation-induced skin reactions (Grade III/IV) or abnormalities in thyroid or estrogen levels were observed.

Conclusion: In this small retrospective series, single-dose 8 Gy brachytherapy administered within 8 h after surgical excision was associated with a high response rate and no severe adverse events. These findings suggest it may be a potentially useful outpatient treatment option for keloids, though further comparative studies are needed to confirm its efficacy and safety.

Background: Acne vulgaris is one of the most prevalent disorders affecting 9%-10% of the global population, representing as papules, pustules, and comedones, with a pathogenesis involving increased sebum production, C. acnes colonization, and inflammation. Conventional treatments like retinoids and antibiotics often cause side effects, thus diverting attention toward probiotics as an alternative therapy. Lactobacillus probiotics, having their immunomodulatory, anti-inflammatory, and antimicrobial properties, are useful in managing acne by reducing inflammation and oxidative stress with proved safety profile and the potential to reduce antibiotic reliance. This systematic review and meta-analysis evaluate the efficacy of Lactobacillus-based probiotics compared to placebo and benzoyl peroxide in reducing inflammatory lesions, non-inflammatory lesions, and total acne lesion counts. The findings aim to clarify their therapeutic role and provide evidence on their effectiveness and safety.

Objectives: This systematic review and meta-analysis investigated the effectiveness of oral and topical Lactobacillus-based probiotics or postbiotics, compared with placebo or benzoyl peroxide, in patients with acne vulgaris.

Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, including studies evaluating oral or topical Lactobacillus-based probiotic or postbiotic interventions in patients with acne vulgaris. Primary outcomes were changes in inflammatory lesion counts, while secondary outcomes included non-inflammatory and total lesion counts, skin hydration, and sebum concentration. All analyses were performed using random-effects models with 95% confidence intervals (CI), and heterogeneity was quantified using the I² statistic.

Results: A total of five RCTs involving 332 participants were included. The pooled mean difference for non-inflammatory lesions was -1.39 (95% CI -5.10 to 2.32, p = 0.46), for inflammatory lesions was -0.08 (95% CI -1.28 to 1.11, p = 0.89), and for total lesion counts was -9.07 (95% CI -20.71 to 2.57, p = 0.13). These results concluded that there was no significant reduction in lesion counts with Lactobacillus-based probiotics as compared to placebo or benzoyl peroxide. Heterogeneity was moderate to low across studies.

Conclusion: This meta-analysis indicates that Lactobacillus-based probiotics do not provide significant clinical benefits in reducing inflammatory lesions, non-inflammatory lesions, and total acne lesion counts in Acne vulgaris patients compared to placebo or benzoyl peroxide.